Ukena D, Wehinger C, Engelstätter R, Steinijans V, Sybrecht G W
Medizinische Universitätsklinik, Innere Medizin V, Homburg, Germany.
Eur Respir J. 1993 Mar;6(3):378-82.
In a double-blind, placebo-controlled, randomized, cross-over trial, we studied the effects of the muscarinic M1-receptor-selective antagonist (+/-)-telenzepine (3 mg orally at 6 p.m. for 5 days) in 21 patients with chronic obstructive pulmonary disease (COPD). At enrollment all patients showed at least a 50% decrease in airway resistance (Raw) after inhalation of 400 micrograms fenoterol or 200 micrograms oxitropium bromide. Telenzepine did not have a significant effect on forced expiratory volume in one second (FEV1) or forced vital capacity (FVC). Also, no significant changes could be detected in daily spirometric profiles or Raw. The results indicate that short-term treatment with the M1-selective antagonist, telenzepine, does not improve airway function in COPD patients, at least after administration by the oral route.
在一项双盲、安慰剂对照、随机、交叉试验中，我们研究了毒蕈碱M1受体选择性拮抗剂（±）-替仑西平（下午6点口服3毫克，持续5天）对21例慢性阻塞性肺疾病（COPD）患者的影响。入组时，所有患者在吸入400微克非诺特罗或200微克氧托溴铵后气道阻力（Raw）至少降低50%。替仑西平对一秒用力呼气容积（FEV1）或用力肺活量（FVC）没有显著影响。此外，在每日肺量计检查结果或Raw中也未检测到显著变化。结果表明，至少经口服途径给药后，M1选择性拮抗剂替仑西平的短期治疗并不能改善COPD患者的气道功能。
